한글목차

TNF 알파 억제제의 동향과 전망

세계 TNF 알파 억제제 시장의 미래는 염증성 장질환, 건선성 관절염, 궤양성 대장염, 류마티스 관절염, 강직성 척추염 시장에 기회가 있어 유망합니다. 세계 TNF 알파 억제제 시장은 2024년부터 2030년까지 연평균 2.4%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 염증성 질환의 발생률 증가, 생명 공학 분야의 발전, 노인 인구 증가입니다.

• Lucintel의 예측에 따르면, Remicade(인플릭시맙)는 예측 기간 동안 의약품 카테고리에서 가장 높은 성장세를 보일 것으로 예상됩니다.
• 유형별로는 염증성 장질환이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것입니다.

TNF 알파 억제제 시장에서의 전략적 성장 기회

TNF 알파 억제제 시장의 주요 전략적 성장 기회는 다음과 같습니다.

• 자가면역질환 관리: 류마티스 관절염, 건선 등 자가면역질환 관리에서 TNF 알파 억제제 사용 증가는 큰 성장 기회가 될 것입니다. 이러한 치료제는 환자의 삶의 질을 개선하는 동시에 질환의 진행을 지연시킵니다.
• 염증성 장질환(IBD) : 크론병과 궤양성 대장염을 포함한 IBD의 발병률 증가는 TNF 알파 억제제에 대한 수요를 촉진하고 있습니다. 이 분야는 특히 새로운 제형과 전달 방법의 개발로 인해 큰 성장 잠재력을 가지고 있습니다.
• 소아 적용: 소아용 TNF 알파 억제제 연구는 기존 '성인 전용' 가이드라인에서 치료 대상에서 제외된 소아 만성질환 환자들에게 치료 옵션을 확대할 수 있습니다. 소아에 대한 승인이 증가하면 이 분야의 치료 성과가 향상될 수 있습니다.
• 병용요법: TNF 알파 억제제는 다른 생물학적 제제나 저분자 화합물과 함께 사용하면 더 높은 효과를 기대할 수 있습니다. 향후 시장 확대는 이러한 혁신적 접근 방식을 통해 촉진될 수 있으며, 대형 브랜드와 중소기업과의 제휴를 통해 치료 경험을 개선하기 위한 맞춤형 솔루션이 개발될 수 있습니다.
• 신흥 시장 : 자가면역질환과 염증성 질환의 발병률이 증가하고 있는 신흥국에서는 저가의 바이오시밀러 의약품이 시장 점유율을 확보할 가능성이 높습니다. 신흥 시장에서 이러한 치료제에 대한 접근성 확대가 성장의 원동력이 될 것입니다.

이러한 전략은 TNF 알파 억제제 시장을 확대하고, 기술 혁신을 촉진하고, 치료 접근성을 확대함으로써 기존 치료법으로 충분한 효과를 얻지 못하는 환자들의 의료 수요를 충족시킬 수 있습니다.

TNF 알파 억제제 시장 성장 촉진요인 및 과제

기술 발전, 경제적 과제, 규제 문제 등 다양한 요인들이 TNF 알파 억제제 시장에 영향을 미치고 있습니다. 이는 시장의 성장과 확장을 결정하는 중요한 요소입니다.

TNF 알파 억제제 시장을 주도하는 요인은 다음과 같습니다.

1. 자가면역질환 증가: 자가면역질환 증가: 자가면역질환 증가는 치료의 일환으로 TNF 알파 억제제에 대한 수요를 촉진하는 중요한 요인입니다.

2. 바이오시밀러의 도입: 바이오시밀러의 도입으로 치료비용이 절감되고, TNF 알파 억제제가 더 많은 사람들이 쉽게 이용할 수 있게 되었으며, 시장 경쟁도 치열해지고 있습니다.

3. 기술 발전: 약물 전달 시스템의 피하주사 등 기술 혁신으로 환자의 치료 성과와 치료 프로토콜 준수율이 향상되었습니다.

4. 우호적인 규제 환경: 주요 시장의 양호한 규제 환경은 TNF 알파 억제제의 승인 과정과 시장 진입을 가속화하고 있습니다.

5. 인구 고령화: 염증 및 자가면역질환에 취약한 노인 인구 증가가 TNF 알파 억제제 수요 증가를 견인하고 있습니다.

TNF 알파 억제제 시장의 과제는 다음과 같습니다.

1. 시장 포화: TNF 알파 억제제 증가로 시장은 포화상태에 이르렀고, 제약기업간 경쟁이 심화되어 가격 압력이 증가하고 있습니다.

2. 바이오시밀러에 대한 우려: 바이오시밀러 제제는 저렴한 가격에도 불구하고 의료진과 일부 환자들은 바이오시밀러 제제의 효과에 대한 우려로 인해 바이오시밀러 제제의 전면적인 채택을 주저하고 있습니다.

3. 규제 장벽: TNF 알파 억제제는 지역별로 상이한 복잡한 규제 요건을 통과하는 것이 시장 진입을 지연시키거나 개발 비용을 증가시킬 수 있습니다.

이러한 도전에도 불구하고 기업들은 시장 성장 촉진요인과 과제를 완화하기 위해 노력하고 있으며, 시장은 계속 성장하고 있습니다.

목차

제1장 주요 요약

제2장 세계의 TNF 알파 억제제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 TNF 알파 억제제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 TNF 알파 억제제 시장 : 약제별
  • Remicade (Infliximab)
  • Enbrel (Etanercept)
  • Humira (Adalimumab)
  • Cimzia (Certolizumab Pegol)
  • Simponi (Golimumab)
• 세계의 TNF 알파 억제제 시장 : 투여 경로별
  • 경구
  • 피하
  • 정맥내
  • 기타
• 세계의 TNF 알파 억제제 시장 : 질환 유형별
  • 염증성 장질환
  • 건선성 관절염
  • 궤양성 대장염
  • 류마티스 관절염
  • 강직성 척추염
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 TNF 알파 억제제 시장 : 지역별
• 북미의 TNF 알파 억제제 시장
• 유럽의 TNF 알파 억제제 시장
• 아시아태평양의 TNF 알파 억제제 시장
• 기타 지역의 TNF 알파 억제제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 TNF 알파 억제제 시장 성장 기회 : 약제별
  • 세계의 TNF 알파 억제제 시장 성장 기회 : 투여 경로별
  • 세계의 TNF 알파 억제제 시장 성장 기회 : 질환 유형별
  • 세계의 TNF 알파 억제제 시장 성장 기회 : 지역별
• 세계 TNF 알파 억제제 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 TNF 알파 억제제 시장 생산능력 확대
  • 세계 TNF 알파 억제제 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• HanAll Biopharma
• Pfizer
• Johnson & Johnson
• Janssen Biotech
• Merck
• AbbVie
• Novartis International
• Sanofi
• AstraZeneca
• GlaxoSmithKline

영문목차

TNF Alpha Inhibitor Trends and Forecast

The future of the global TNF alpha inhibitor market looks promising with opportunities in the inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis markets. The global TNF alpha inhibitor market is expected to grow with a CAGR of 2.4% from 2024 to 2030. The major drivers for this market are rising rates of inflammatory illnesses, increasing progress in the field of biotechnology, and a growing number of elderly people.

• Lucintel forecasts that, within the drug category, Remicade (infliximab) is expected to witness the highest growth over the forecast period.
• Within the type category, inflammatory bowel disease is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the TNF Alpha Inhibitor Market

Emerging trends in the TNF alpha inhibitor market are reshaping its future applications and dynamics:

• Biosimilar Expansion: The global expansion of TNF alpha inhibitors is leading to lower treatment costs and better access, especially in emerging markets. This trend promotes competition, which reduces prices, making treatments more accessible for chronic conditions.
• Personalized Medicine: Advancements in genetic testing and biomarkers are driving personalized approaches to TNF-alpha inhibitor therapy. This helps optimize therapeutic efficacy and patient outcomes by tailoring therapies to individual patient profiles.
• New Indications: Ongoing research is expanding the therapeutic applications of TNF alpha inhibitors beyond traditional autoimmune diseases, including dermatology and oncology. This creates novel market opportunities and drives innovation in drug development.
• Subcutaneous Formulations: The advent of subcutaneous forms of TNF-alpha inhibitors has increased patient convenience and medication adherence. This is particularly important for chronic diseases, where long-term treatment is required, and patient compliance is crucial for improving overall well-being.
• Regulatory Harmonization: Efforts to harmonize regional regulatory frameworks have streamlined the approval process for TNF alpha inhibitors. This has sped up the time-to-market for new products and biosimilars globally.

All of these trends are shaping the TNF alpha inhibitor market in terms of accessibility, personalization, and convenience, while also driving innovation and competition in global healthcare.

Recent Developments in the TNF Alpha Inhibitor Market

Ongoing innovations and advancements in the TNF alpha inhibitor market include:

• Biosimilar Approvals: Approved TNF-alpha inhibitors in the US and Europe have intensified competition, leading to lower treatment costs and broader patient access, especially for conditions such as rheumatoid arthritis and psoriasis.
• Reforms by China's Regulatory Agency: China's regulatory reforms have expedited the approval and commercialization of both originators and biosimilars of TNF alpha inhibitors, enhancing local production capabilities and reducing dependence on imports.
• New Indications in Germany: In Germany, there is an increasing number of new indications for which approval has been granted to use TNF alpha inhibitors, including non-rheumatic inflammatory diseases. These innovations broaden the clinical usefulness of TNF alpha inhibitors.
• India's Market Expansion: The rapid introduction of affordable TNF alpha inhibitors in India, driven by the country's growing pharmaceutical industry, has improved access to these drugs for rural populations with low incomes, addressing unmet medical needs.

These strides will significantly transform the future direction of markets for critical medications like TNF alpha inhibitors, making them more affordable and accessible in a shorter period, and expanding their reach to more areas.

Strategic Growth Opportunities for TNF Alpha Inhibitor Market

Some key strategic growth opportunities in the TNF alpha inhibitor market include:

• Autoimmune Disease Management: The increased use of TNF-alpha inhibitors in managing autoimmune diseases such as rheumatoid arthritis and psoriasis presents a major growth opportunity. These therapies improve patients' quality of life while decelerating the progression of the diseases.
• Inflammatory Bowel Disease (IBD): The rising incidence of IBD, including Crohn's disease and ulcerative colitis, has spurred demand for TNF alpha inhibitors. This area offers substantial growth potential, especially with the development of new formulations and delivery methods.
• Pediatric Applications: Research into TNF alpha inhibitors for pediatric use could expand therapeutic options for children diagnosed with chronic illnesses who would otherwise be excluded from treatments under conventional "adults-only" guidelines. Increasing approvals for pediatric use could enhance outcomes in this specialty.
• Combination Therapies: TNF alpha inhibitors can have enhanced efficacy when paired with other biologics or small molecules. Future market expansion may be driven by this innovative approach, with partnerships between larger brands and smaller companies developing tailored solutions for improved treatment experiences.
• Emerging Markets: In developing economies, where the incidence of autoimmune diseases and inflammatory conditions is increasing, low-cost biosimilars are likely to capture market share. Expanding access to these therapies in emerging markets will drive growth.

These strategies will broaden the market for TNF alpha inhibitors, spark innovation, and provide greater access to therapies, addressing the medical needs of patients who are not fully served by existing treatments.

TNF Alpha Inhibitor Market Driver and Challenges

A variety of factors, including technological advancements, economic challenges, and regulatory issues, influence the TNF alpha inhibitor market. These are crucial determinants of market growth and expansion.

The factors driving the TNF alpha inhibitor market include:

1. Increasing Occurrence of Autoimmune Diseases: The rising prevalence of autoimmune diseases is a key factor driving the demand for TNF alpha inhibitors as part of the treatment process.

2. Biosimilars Adoption: The introduction of biosimilars has reduced treatment costs, making TNF alpha inhibitors more accessible to a broader population and increasing competition in the market.

3. Advancement in Technology: Innovations, such as subcutaneous injections for drug delivery systems, have improved patient outcomes and compliance with treatment protocols.

4. Supportive Regulatory Environment: Favorable regulatory environments in major markets have accelerated the approval process and market entry for TNF alpha inhibitors.

5. Aging Population: The increasing elderly population, who are more prone to inflammation and autoimmune conditions, is driving greater demand for TNF alpha inhibitors.

Challenges in the TNF alpha inhibitor market include:

1. Market Saturation: The growing number of TNF alpha inhibitors has led to market saturation, increasing competition among pharmaceutical companies and creating price pressure.

2. Concerns Over Biosimilars: Despite their lower prices, healthcare providers and some patients remain hesitant to fully embrace biosimilars, citing concerns about their efficacy, which slows their adoption rates.

3. Regulatory Barriers: Navigating complex and varying regulatory requirements across regions can delay market entry or increase development costs for TNF alpha inhibitors.

Despite these challenges, the market continues to grow as companies leverage the drivers and work to mitigate these obstacles.

List of TNF Alpha Inhibitor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies TNF alpha inhibitor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the TNF alpha inhibitor companies profiled in this report include-

• HanAll Biopharma
• Pfizer
• Johnson & Johnson
• Janssen Biotech
• Merck
• AbbVie
• Novartis International
• Sanofi
• AstraZeneca
• GlaxoSmithKline

TNF Alpha Inhibitor by Segment

The study includes a forecast for the global TNF alpha inhibitor by drug, route of administration, disease type, and region.

TNF Alpha Inhibitor Market by Drug [Analysis by Value from 2018 to 2030]:

• Remicade (Infliximab)
• Enbrel (Etanercept)
• Humira (Adalimumab)
• Cimzia (Certolizumab Pegol)
• Simponi (Golimumab)

TNF Alpha Inhibitor Market by Route of Administration [Analysis by Value from 2018 to 2030]:

• Oral
• Subcutaneous
• Intravenous
• Others

TNF Alpha Inhibitor Market by Disease Type [Analysis by Value from 2018 to 2030]:

• Inflammatory Bowel Disease
• Psoriatic Arthritis
• Ulcerative Colitis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Others

TNF Alpha Inhibitor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the TNF Alpha Inhibitor Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major TNF alpha inhibitor producers in key regions: the USA, China, India, Japan, and Germany:

• United States: In the US, approval of TNF alpha inhibitors has led to increased competition and reduced costs. These developments are improving access for patients, particularly for chronic diseases like rheumatoid arthritis and Crohn's disease while driving innovation in delivery mechanisms and formulation improvements.
• China: Regulatory reforms in China have fast-tracked the approval process for TNF alpha inhibitors, resulting in the launch of both local and international products. The focus is on affordability and increasing the accessibility of biological therapies for autoimmune conditions, with an emphasis on locally produced drugs.
• Germany: Biosimilar adoption in Germany has been strong, driven by favorable reimbursement policies. Recent advances include expanding the indications for existing drugs, backed by substantial clinical evidence, thereby enhancing their integration into treatment protocols.
• India: India has become a major manufacturer of low-cost TNF alpha inhibitors, with several biosimilars already available in the market. Pharmaceutical regulations have been streamlined, and efforts are now focused on improving the distribution of these treatments in rural areas and other underserved populations.
• Japan: Japan is seeing a transformation in the TNF alpha inhibitor market through the development of biosimilars and novel formulations. Recent government initiatives are promoting the use of biosimilars as cost-saving alternatives. Clinical trials are ongoing to expand the therapeutic applications of TNF alpha inhibitors in Japan.

Features of the Global TNF Alpha Inhibitor Market

Market Size Estimates: TNF alpha inhibitor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: TNF alpha inhibitor market size by drug, route of administration, disease type, and region in terms of value ($B).

Regional Analysis: TNF alpha inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drugs, route of administrations, disease types, and regions for the TNF alpha inhibitor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the TNF alpha inhibitor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the TNF alpha inhibitor market by drug (remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), and simponi (golimumab)), route of administration (oral, subcutaneous, intravenous, and others), disease type (inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global TNF Alpha Inhibitor Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global TNF Alpha Inhibitor Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global TNF Alpha Inhibitor Market by Drug
  • 3.3.1: Remicade (Infliximab)
  • 3.3.2: Enbrel (Etanercept)
  • 3.3.3: Humira (Adalimumab)
  • 3.3.4: Cimzia (Certolizumab Pegol)
  • 3.3.5: Simponi (Golimumab)
• 3.4: Global TNF Alpha Inhibitor Market by Route of Administration
  • 3.4.1: Oral
  • 3.4.2: Subcutaneous
  • 3.4.3: Intravenous
  • 3.4.4: Others
• 3.5: Global TNF Alpha Inhibitor Market by Disease Type
  • 3.5.1: Inflammatory Bowel Disease
  • 3.5.2: Psoriatic Arthritis
  • 3.5.3: Ulcerative Colitis
  • 3.5.4: Rheumatoid Arthritis
  • 3.5.5: Ankylosing Spondylitis
  • 3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global TNF Alpha Inhibitor Market by Region
• 4.2: North American TNF Alpha Inhibitor Market
  • 4.2.1: North American Market by Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), and Simponi (Golimumab)
  • 4.2.2: North American Market by Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others
• 4.3: European TNF Alpha Inhibitor Market
  • 4.3.1: European Market by Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), and Simponi (Golimumab)
  • 4.3.2: European Market by Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others
• 4.4: APAC TNF Alpha Inhibitor Market
  • 4.4.1: APAC Market by Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), and Simponi (Golimumab)
  • 4.4.2: APAC Market by Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others
• 4.5: ROW TNF Alpha Inhibitor Market
  • 4.5.1: ROW Market by Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), and Simponi (Golimumab)
  • 4.5.2: ROW Market by Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global TNF Alpha Inhibitor Market by Drug
  • 6.1.2: Growth Opportunities for the Global TNF Alpha Inhibitor Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global TNF Alpha Inhibitor Market by Disease Type
  • 6.1.4: Growth Opportunities for the Global TNF Alpha Inhibitor Market by Region
• 6.2: Emerging Trends in the Global TNF Alpha Inhibitor Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global TNF Alpha Inhibitor Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global TNF Alpha Inhibitor Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: HanAll Biopharma
• 7.2: Pfizer
• 7.3: Johnson & Johnson
• 7.4: Janssen Biotech
• 7.5: Merck
• 7.6: AbbVie
• 7.7: Novartis International
• 7.8: Sanofi
• 7.9: AstraZeneca
• 7.10: GlaxoSmithKline